MedPath

Jiangsu vcare pharmaceutical technology co., LTD

Ownership
Private
Employees
-
Market Cap
-
Website

Efficacy and Safety Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.

Phase 2
Completed
Conditions
Active Ankylosing Spondylitis
Interventions
Drug: VC005 Tablets Placebo
Drug: VC005 tablets
First Posted Date
2023-04-18
Last Posted Date
2024-07-29
Lead Sponsor
Jiangsu vcare pharmaceutical technology co., LTD
Target Recruit Count
180
Registration Number
NCT05814939
Locations
πŸ‡¨πŸ‡³

Peking University People's Hospital, Beijing, Beijing, China

Assessment of the Effect of Omeprazole on Vicagrel in Healthy Subjects

Phase 1
Recruiting
Conditions
Healthy Subjects
Interventions
First Posted Date
2022-12-14
Last Posted Date
2023-01-31
Lead Sponsor
Jiangsu vcare pharmaceutical technology co., LTD
Target Recruit Count
20
Registration Number
NCT05651074
Locations
πŸ‡¨πŸ‡³

Phase I Clinical Research Center of The First Hospital of Jilin University, Chang chun, Jilin, China

Food Effect Study on the Pharmacokinetics of VC004 Capsules in Healthy Adult Subjects

Phase 1
Completed
Conditions
Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion
Interventions
Drug: VC004 Capsules
First Posted Date
2022-09-06
Last Posted Date
2022-11-30
Lead Sponsor
Jiangsu vcare pharmaceutical technology co., LTD
Target Recruit Count
16
Registration Number
NCT05528120
Locations
πŸ‡¨πŸ‡³

Zhongda Hospital,Affiliated to Southeast University, Nanjing, Jiangsu, China

Multiple-dose Escalation Clinical Study of VC005 Tablets in Healthy Subjects

Phase 1
Completed
Conditions
Inflammatory Bowel Diseases
Interventions
Drug: VC005 Placebo tablets
Drug: VC005 tablets
First Posted Date
2022-04-29
Last Posted Date
2022-11-17
Lead Sponsor
Jiangsu vcare pharmaceutical technology co., LTD
Target Recruit Count
60
Registration Number
NCT05354752
Locations
πŸ‡¨πŸ‡³

The First Hospital of Jilin University, Changchun, Jilin, China

PK/PD Study of Vicagrel and Clopidogrel in Healthy Subjects With Different CYP2C19 Metabolizers

Phase 1
Completed
Conditions
Acute Coronary Syndrome
Interventions
First Posted Date
2021-12-17
Last Posted Date
2023-11-03
Lead Sponsor
Jiangsu vcare pharmaceutical technology co., LTD
Target Recruit Count
128
Registration Number
NCT05162053
Locations
πŸ‡ΊπŸ‡Έ

Altasciences, Kansas City, Kansas City, Missouri, United States

πŸ‡ΊπŸ‡Έ

Altasciences Clinical, Los Angeles, Los Angeles, California, United States

πŸ‡¨πŸ‡³

Phase I Clinical Research Center of The First Hospital of Jilin University, Changchun, Jilin, China

Pharmacokinetics and Pharmacodynamics Clinical Study of VC005 Tablets in Healthy Subjects

Phase 1
Completed
Conditions
Inflammatory Bowel Diseases
Interventions
Drug: VC005 Tablets
Drug: VC005 Tablets Placebo
Drug: VC005 Tablets food effects group
First Posted Date
2021-12-01
Last Posted Date
2022-09-02
Lead Sponsor
Jiangsu vcare pharmaceutical technology co., LTD
Target Recruit Count
78
Registration Number
NCT05138770
Locations
πŸ‡¨πŸ‡³

The First Hospital of Jilin University, Changchun, Jilin, China

A Clinical Trial to Evaluate the Effect of Food on PK and PD of Vicagrel Capsules in Healthy Adult Subjects

Phase 1
Completed
Conditions
Acute Coronary Syndrome
Interventions
First Posted Date
2021-06-09
Last Posted Date
2021-11-01
Lead Sponsor
Jiangsu vcare pharmaceutical technology co., LTD
Target Recruit Count
24
Registration Number
NCT04919551
Locations
πŸ‡¨πŸ‡³

The First Hospital of Jilin University, Changchun, Jilin, China

The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors

Phase 1
Recruiting
Conditions
Metastatic Solid Tumor
Locally Advanced Solid Tumor
Interventions
First Posted Date
2020-11-04
Last Posted Date
2022-12-13
Lead Sponsor
Jiangsu vcare pharmaceutical technology co., LTD
Target Recruit Count
115
Registration Number
NCT04614740
Locations
πŸ‡¨πŸ‡³

Anhui Provincial Cancer Hospital, Hefei, Anhui, China

πŸ‡¨πŸ‡³

Hainan Cancer Hospital, Haikou, Hainan, China

πŸ‡¨πŸ‡³

Hubei Cancer Hospital, Wuhan, China

and more 18 locations

The Mass Balance and Biotransformation of [14C] Vicagrel in Healthy Man

Phase 1
Completed
Conditions
Healthy Male Adult
Interventions
Drug: [14C]Vicagrel
First Posted Date
2019-10-29
Last Posted Date
2020-04-03
Lead Sponsor
Jiangsu vcare pharmaceutical technology co., LTD
Target Recruit Count
6
Registration Number
NCT04143750
Locations
πŸ‡¨πŸ‡³

The First Affiliated Hospital of Suzhou University, Suzhou, Jiangsu, China

Pharmacokinetics and Pharmacodynamics of Vicagrel in Healthy Adult Subjects of Different CYP2C19

Phase 1
Completed
Conditions
Healthy Subjects
PK/PD
Interventions
First Posted Date
2019-05-08
Last Posted Date
2019-09-19
Lead Sponsor
Jiangsu vcare pharmaceutical technology co., LTD
Target Recruit Count
50
Registration Number
NCT03942458
Locations
πŸ‡¨πŸ‡³

The First Hospital of Jilin University, Chang chun, Jilin, China

Β© Copyright 2025. All Rights Reserved by MedPath